While in myeloma patients there were no significant differences in engraftment kinetics or transfusion requirements between the Plerixafor Group and the G-CSF Group, lymphoma patients not requiring Plerixafor showed significantly faster neutrophil recovery, a trend to faster platelet recovery, and a significantly lower need for platelet transfusions (Table 3 and Table 4). This evidence concerns the gene CSF3 and plasma cell myeloma.